ACAD ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. (ACAD) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 25% planned / 75% discretionary
Largest single sale: $671.0K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Schneyer Mark C. 2 fills | EVP, CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 14,292 | $29.22 | $417.6K | 77,120 −15.6% of holding | |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 5,849 | $29.00 | $169.6K | 67,828 −7.9% of holding | |
| Thompson Elizabeth H.Z. 2 fills | EVP, Head of Research & Dev | Sell | 16,558 | $26.13 | $432.7K | 19,044 −46.5% of holding | |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell 10b5-1 | 11,421 | $26.08 | $297.9K | 13,088 −46.6% of holding | |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 5,401 | $21.18 | $114.4K | 24,509 −18.1% of holding | |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,506 | $21.79 | $76.4K | 66,145 −5% of holding | |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,332 | $21.79 | $29.0K | 29,129 −4.4% of holding | |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 2,709 | $22.20 | $60.1K | 62,836 −4.1% of holding | |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,030 | $22.20 | $22.9K | 27,865 −3.6% of holding | |
| Schneyer Mark C. 2 fills | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,208 | $21.65 | $69.5K | 60,306 −5.1% of holding | |
| Kihara James 2 fills | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,109 | $21.65 | $24.0K | 26,897 −4% of holding | |
| Owen Adams Catherine | Chief Executive Officer | Sell | 11,641 | $21.47 | $249.9K | 14,803 −44% of holding | |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 4,177 | $21.47 | $89.7K | 57,299 −6.8% of holding | |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | Sell | 3,844 | $21.47 | $82.5K | 11,280 −25.4% of holding | |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sell | 3,435 | $21.47 | $73.7K | 3,280 −51.2% of holding | |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 833 | $21.47 | $17.9K | 25,852 −3.1% of holding | |
| Rhodes Jennifer J | EVP, CHIEF LEGAL OFFICER, SEC | Sell | 6,950 | $23.38 | $162.5K | 7,609 −47.7% of holding | |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 10,262 | $23.69 | $243.1K | 53,338 −16.1% of holding | |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 4,084 | $23.69 | $96.8K | 25,058 −14% of holding | |
| Daly James M | Director | Sell | 30,000 | $22.37 | $671.0K | 4,041 −88.1% of holding | |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,498 | $23.65 | $82.7K | 43,447 −7.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.